Biotech & Life Sciences

When colon tissue heals, it looks fine.

When brexanolone won FDA approval in 2019 as the first-ever treatment specifically for postpartum depression, it felt like the opening of a new chapter in neuropsychiatry.

For the estimated three million Americans with a form of heart failure where the heart pumps normally but the body never quite gets enough oxygen, diagnosis has always been more art than science.

Women with platinum-resistant ovarian cancer have run out of effective options — and for years, the drugs that remained barely worked.

The Food and Drug Administration on Wednesday approved a new therapy from Denali Therapeutics for Hunter syndrome, clearing a drug that can do something no existing treatment for the disease has ever managed: reach the brain. Avlayah (tividenofusp alfa-eknm) is an enzyme replacement therapy desi...

For people living with alpha-1 antitrypsin deficiency, the disease is a slow-motion double insult: the lungs erode without protection, and the liver accumulates a misfolded protein it cannot clear.

Xaira Therapeutics thinks it has found the secret to predicting how cells respond to drugs: go bigger.

Merck's $6.7 billion acquisition of Terns Pharmaceuticals, announced this week, is not a pipeline deal.

Sixty years into its clinical life, metformin still had a secret. Researchers at Baylor College of Medicine, working with collaborators at Louisiana State University, Nagoya University, and Meiji University in Japan, have found that metformin — the world's most prescribed diabetes drug — works i...

Paris-based Bioptimus has announced a plan to build the world's largest spatially-anchored map of human tissue at clinical scale: 100,000 patient specimens, spanning the United States, Europe, and Asia.

Kali Therapeutics' experimental drug KT501 entered human testing on March 18, 2026 — the first patient dosed in a Phase Ia study in rheumatoid arthritis — and within hours, Sanofi confirmed it had secured the worldwide license.